Skip to main content
Clinical Trials/NCT05055999
NCT05055999
Completed
Not Applicable

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy

Hunan Province Tumor Hospital1 site in 1 country60 target enrollmentApril 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Extensive Stage Small Cell Lung Cancer
Sponsor
Hunan Province Tumor Hospital
Enrollment
60
Locations
1
Primary Endpoint
PFS
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.

Registry
clinicaltrials.gov
Start Date
April 1, 2019
End Date
September 1, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hunan Province Tumor Hospital
Responsible Party
Principal Investigator
Principal Investigator

Yongchang Zhang

Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Hunan Province Tumor Hospital

Eligibility Criteria

Inclusion Criteria

  • 18, Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy

Exclusion Criteria

  • Patients with contraindication of chemotherapy Pregnant or breast feeding women

Outcomes

Primary Outcomes

PFS

Time Frame: April 2019- July 2021

Progression free survival

OS

Time Frame: April 2019- July 2021

Overall survival

Study Sites (1)

Loading locations...

Similar Trials